Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms

What changed: Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms

Cancer page →

Every dated change on the records linked to Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval1Regulatory1Guideline1Milestone7This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-10This recordChronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms
Facts on this page last checked
When this page itself was last checked or edited.

2022 · 1

2022MilestoneChronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms
WHO 5th edition and ICC redefine CMML
Monocyte threshold lowered to 0.5 x 10^9/L with molecular support; dysplastic vs proliferative subtypes formalised.

July 2020 · 1

2020-07-07RegulatoryDecitabine + cedazuridine (oral)
Decitabine + cedazuridine (oral): approval (US)
MDS/CMML

2020 · 2

2013 · 1

2013MilestoneChronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms
CPSS risk score for CMML
Such and colleagues; CPSS-Mol adds mutations in 2016.

2004 · 1

2004MilestoneAzacitidine
Azacitidine approved for MDS including CMML
A milestone in how this cancer is treated.

2001 · 1

2001MilestoneChronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms
WHO creates the MDS/MPN category
CMML, atypical CML and JMML grouped as overlap neoplasms.

1996 · 2

1982 · 1

1982MilestoneChronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms
FAB classification includes CMML within MDS
A milestone in how this cancer is treated.